GlassScriptPhysician profile
Michael M Mannino
NPI 1598761660
$20,101.05
in general payments reported to CMS, 2019-2025
36 companies · $3,059 in 2025
The $3,059 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,432 · 2020: $898 · 2021: $4,078 · 2022: $3,891 · 2023: $3,485 · 2024: $3,259 · 2025: $3,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,802.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,976.97 | 2019-2025 | Aveir, Assurity, Merlin@Home |
| Astrazeneca Pharmaceuticals LP | $1,600.20 | 2021-2025 | Farxiga, Lokelma, Wainua |
| Novartis Pharmaceuticals Corporation | $1,587.95 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,436.25 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $911.64 | 2021-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $907.90 | 2021-2025 | Verquvo, Capvaxive |
| Amgen INC. | $887.54 | 2020-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $829.89 | 2019-2025 | Watchman Flx, Cds - Mct/Cem Monitoring, Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $772.57 | 2020-2025 | Jardiance |
| Impulse Dynamics (USA) INC. | $641.90 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $598.39 | 2022-2025 | |
| Pfizer INC. | $597.10 | 2019-2025 | |
| Esperion Therapeutics, INC. | $581.79 | 2021-2025 | Nexletol |
| Medtronic Vascular, INC. | $433.02 | 2019-2020 | |
| Amarin Pharma, INC. | $275.70 | 2021-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $271.05 | 2022-2025 | Rybelsus, Ozempic |
| Medtronic, INC. | $242.61 | 2021-2023 | Cobalt Dr Mri Surescan |
| Sanofi-Aventis U.S. LLC | $231.94 | 2022-2024 | |
| Lexicon Pharmaceuticals, INC. | $222.72 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $186.73 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $163.44 | 2021-2023 | Evkeeza, Praluent |
| Daiichi Sankyo INC. | $107.21 | 2023-2025 | Injectafer |
| Scpharmaceuticals INC. | $107.04 | 2023-2025 | |
| Heartflow, INC. | $99.87 | 2023-2025 | Ffrct |
| Lilly USA, LLC | $92.67 | 2025 | Zepbound |
| Kiniksa Pharmaceuticals, LTD. | $81.07 | 2023 | Arcalyst |
| Kestra Medical Technology Services, INC. | $41.72 | 2022 | |
| Alnylam Pharmaceuticals INC. | $36.05 | 2025 | Amvuttra |
| Cvrx, INC. | $28.63 | 2024 | Barostim Neo System |
| Baxter Healthcare | $27.25 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Althera Pharmaceuticals LLC | $25.84 | 2022 | |
| Chiesi USA, INC. | $22.59 | 2025 | Juxtapid |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.87 | 2025 | Lifevest |
| Inspire Medical Systems, INC. | $19.90 | 2024 | Inspire |
| Bridgebio Pharma, INC. | $19.30 | 2025 | Attruby |
| Preventice Services, LLC | $13.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mannino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.